Search results
Regeneron Pharma earnings missed by $0.64, revenue fell short of estimates By Investing.com
Investing.com· 12 hours agoRegeneron Pharma earnings missed by $0.64, revenue fell short of estimates
Regeneron Reverses On Better-Than-Feared Eylea Sales As Patent Expiration Looms
Investor's Business Daily· 3 hours agoRegeneron Stock: Better Than Feared Abrahams kept his outperform rating and 1,189 price target on ...
Is Weakness In Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock A Sign That The Market Could be...
Simply Wall St. via Yahoo Finance· 11 hours agoIt is hard to get excited after looking at Regeneron Pharmaceuticals' (NASDAQ:REGN) recent...
Regeneron misses earnings, revenue expectations By Investing.com
Investing.com· 12 hours agoRegeneron (NASDAQ:REGN) experienced a slight decline in its stock price, falling 1.82% after...
Regeneron (REGN) Q1 Earnings, Sales Miss on Lower Eylea Sales
Zacks via Yahoo Finance· 9 hours agoThis BLA was also granted priority review with a target action date of Aug 22, 2024. Regeneron...
Regeneron’s stock rallies as pipeline prospects outweigh earnings miss
Market Watch· 12 hours agoThe revenue shortfall was partly due to a decline in sales of the company’s blockbuster eye drug...
Regeneron (REGN) Reports Q1 Earnings: What Key Metrics Have to Say
Zacks via Yahoo Finance· 9 hours agoAlthough the revenue and EPS for Regeneron (REGN) give a sense of how its business performed in the...
3 Biotech Stocks to Buy and Hold Through 2030 and Beyond
Motley Fool via Yahoo Finance· 12 hours agoWith a pipeline that carries several dozen programs, the company should deliver plenty of regulatory...
Checking in on Regeneron Pharmaceuticals, Inc.
Knox Daily· 1 day agoBernstein initiated its Regeneron Pharmaceuticals, Inc. [REGN] rating to an Outperform in a research note published on March 12, 2024; the price target ...
Regeneron Pharmaceuticals (NASDAQ:REGN) PT Raised to $1,030.00 at TD Cowen
ETF DAILY NEWS· 7 days agoThe brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. TD Cowen’s price target suggests a potential upside of 15.64% from ...